

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Pulmagen Therapeutics (Synergy) Limited	08/18/2010
RECEIVING PARTY DATA	
Name:	Domantis Limited
Street Address:	980 Great West Road
Internal Address:	Brentford
City:	Middlesex
State/Country:	UNITED KINGDOM
Postal Code:	TW8 9GS
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12084084
CORRESPONDENCE DATA	
Fax Number:	(610)270-5090
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	610-270-6812
Email:	us_cipkop@gsk.com
Correspondent Name:	GlaxoSmithKline
Address Line 1:	709 Swedeland Road
Address Line 2:	UW2220
Address Line 4:	King of Prussia, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	DB00034/DOMANTIS
NAME OF SUBMITTER:	Deborah A. Becker

CH \$40.00 12084084

Total Attachments: 12
 source=ARGENTA_DOMANTIS_ASSIGNMENT#page1.tif
 source=ARGENTA_DOMANTIS_ASSIGNMENT#page2.tif

501438736

PATENT
REEL: 025809 FRAME: 0197

source=ARGENTA_DOMANTIS_ASSIGNMENT#page3.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page4.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page5.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page6.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page7.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page8.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page9.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page10.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page11.tif
source=ARGENTA_DOMANTIS_ASSIGNMENT#page12.tif

ASSIGNMENT AGREEMENT

This Assignment Agreement (the "Agreement") is made and entered into effective as of 18 August 2010 (the "Effective Date") by and between DOMANTIS LIMITED, a limited company registered in England and Wales located at 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom ("Domantis"), and PULMAGEN THERAPEUTICS (SYNERGY) LIMITED, formerly known as Argenta Discovery Limited, a limited company registered in England and Wales located at 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom ("Argenta").

WITNESSETH:

WHEREAS, Argenta and Domantis are parties to a Joint Development Agreement (the "JDA") that was entered into between Domantis and Etiologics Limited, dated as of 18th October 2004, and novated in its entirety from Etiologics Limited to Argenta by letter of novation dated 11th November 2005; and

WHEREAS, the parties wish to terminate the JDA, and provide for the transition to Domantis of all activities relating to, and all rights in, the Research Programs (as defined below), as further set forth herein; and

WHEREAS, Argenta and Domantis are willing to agree to the foregoing on the terms and conditions set forth herein

NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained herein, Domantis and Argenta agree as follows:

1. DEFINITIONS

The following capitalized terms shall have the meanings indicated for purposes of this Agreement:

1.1 "Affiliate" shall mean, with respect to either Domantis or Argenta any corporation, firm, partnership or other entity, whether de jure or de facto, which at any time directly or indirectly through one or more intermediaries controls, is controlled by or is under common control with a party to this Agreement. An entity shall be deemed to control another entity if it (i) owns, directly or indirectly, at least fifty percent of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of such other entity, or has other comparable ownership interest with respect to any entity other than a corporation; or (ii) has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of the entity.

1.2 "Argenta Technology" shall mean (i) the assays and preclinical models relating to the Targets and Respiratory Disease, and any associated know-how or protocols

relating thereto, and (ii) any and all patents and patent applications that cover such technology; all to the extent that they are owned by Argenta or licensed to Argenta (with the right to grant sublicenses) as of the Effective Date of this Agreement.

1.3 "Collaboration Lead" shall mean the Domain Antibody known as GSK1995057 and any other Domain Antibody that (i) had been tested or evaluated by the Parties in the course of the performance of the Research Programmes and (ii) Domantis or its Affiliates declare as a selected candidate in the Field in accordance with its usual procedures (or initiate a clinical study in the Field) as a substitute for, or in addition to, GSK1995057.

1.4 "Domain Antibody" shall mean any human single variable VH or VL sequence (and the protein encoded by such sequence) that specifically binds to a Target and was discovered by Domantis or its Affiliates using the Domantis Technology.

1.5 "Domantis Technology" shall mean (i) the libraries of human single variable VH or VL and all VH or VL sequences contained within such libraries (and proteins encoded by such sequences), including without limitation all Collaboration Leads, (ii) any uses, formats, formulations, manufacturing methods and delivery methods with respect to VH or VL sequences and proteins encoded by such sequences (other than any uses of Target, or Collaboration Leads which were developed in the course of performance of a Research Program) and any associated know-how and protocols relating thereto, and (iii) any and all patents and patent applications that cover such technology; all to the extent they are owned by Domantis or licensed to Domantis from a party other than Argenta (with the right to grant sublicenses).

1.6 "Field" shall mean the prevention, treatment or mitigation of Respiratory Disease in humans by Pulmonary Delivery.

1.7 "Joint Patents" shall mean all current and future patents and patent applications to the extent they claim Program Results, together with all additions, divisions, continuations, continuations-in-part, provisionals, substitutions, reissues, re-examinations, extensions, restorations by existing or future extension or restoration mechanisms, registrations, patent term extensions, supplemental protection certificates or the equivalent thereof, and renewals of a patent or patent application, inventor's certificates, and any confirmation patent or registration patent or patent of addition based on any such patent, or any other patent claiming priority from any of the foregoing. For the avoidance of doubt, Joint Patents include, but are not limited to, those patents and patent applications set forth in Appendix A hereto.

1.8 "Joint Property" shall mean all Program Results and Joint Patents, including for the avoidance of doubt, all and any patentable inventions and/or other proprietary rights in and to the Program Results.

1.9 "Party" shall mean Argenta or Domantis individually, and "Parties" shall mean Argenta and Domantis collectively.

1.10 "Product" means any product that is, contains or is directly derived from any Collaboration Lead and which is used, manufactured, sold or otherwise disposed of in the Field by Domantis and/or its Affiliates or their respective licensees.

1.11 "Program Results" shall mean all information, materials, inventions and know-how relating to the role or uses of the Target(s), Collaboration Leads(s) and/or Product(s) that were developed by the Parties in the course of the performance of the Research Programs or as otherwise envisaged by the JDA, excluding any Domantis Technology or Argenta Technology.

1.12 "Pulmonary Delivery" shall mean the administration of an agent solely via inhalation into the lungs notwithstanding the fact that an agent intended to be administered solely by inhalation may actually be partially swallowed by the user in pharmaceutically relevant quantities.

1.13 "Research Program" shall mean each of the collaborative programs for the discovery of the role of the Targets in Respiratory Disease and the investigation of the potential use of Domain Antibodies against such Targets for use in the Field that was conducted by Domantis and/or Argenta pursuant to or as otherwise envisaged by the JDA. For the avoidance of doubt, the phrase "Research Program" shall be deemed to include both "Research Program" and "Development Program" as defined in the JDA.

1.14 "Respiratory Disease" shall mean any human disease or condition that has as its primary outcome the reduction of normal lung function, such as chronic obstructive pulmonary disease, cystic fibrosis, severe steroid-resistant asthmas, but specifically excluding cancers.

1.15 "Target" shall mean TNF Receptor 1 (P55) and/or Interleukin-1 Receptor.

1.16 "Third Party" means an entity other than: (i) Domantis; (ii) Argenta; or (iii) any Affiliate of Domantis or Argenta. The phrase "Third Parties" shall be construed accordingly.

1.17 "VAT" means the tax imposed by Council Directive 2006/112/EC of the European Community and any national legislation implementing that directive together with legislation supplemental thereto and in particular, in relation to the United Kingdom, the tax imposed by the Value Added Tax Act of 1994 or other tax of a similar nature imposed elsewhere instead of or in addition to value added tax.

2. CLOSE OUT OF JDA

2.1 Termination of JDA. The Parties agree that the JDA will be terminated in its entirety, subject to the terms of this Agreement, as of the Effective Date.

2.2 Past and Future Expenses. The Parties agree that as of the Effective Date neither Party is due any money from the other Party under the JDA including, without limitation, under Clauses 2.6, 3, 4.4, 4.5 and 6 of the JDA. For the avoidance of doubt, the

Parties further agree that after the Effective Date, Argenta will have no responsibility for any expenses relating to, nor any right to benefit from, the further development or commercialisation of the Joint Property, Collaboration Leads or Products.

2.3 Mutual Release. Each Party hereby forever releases and discharges and holds harmless the other Party and its Affiliates from any Liabilities, that such Party now or ever could claim against the other Party or its Affiliates arising out of or related to the JDA, with the exception of the obligations as stated within this Agreement. "Liabilities" shall mean liabilities of any kind or nature, primary or secondary, direct or indirect, absolute or contingent, including but not limited to, any liabilities for claims of product liability, personal injury or death, liability in tort or contract (including liabilities due to known past actions), indebtedness, and any regulatory or other governmental agency action or notification, and all costs and expenses (including reasonable attorneys' fees), incurred in connection with the defence of any such claims. For the avoidance of doubt, neither party is released from any Liability that cannot by applicable law be excluded or limited by contract.

3. LICENSE RIGHTS & COMMITMENT

3.1 Assignment of Joint Property to Domantis.

(a) Subject to payment in full by Domantis of the sums referred to in Clause 4.2 below, Argenta, as joint legal and beneficial owner with Domantis, hereby assigns to Domantis all its right, title and interest in and to the Program Results and the full unfettered and exclusive right throughout the world to use the Program Results for any purpose whatsoever.

(b) Subject to payment in full by Domantis of the sums referred to in Clause 4.2 below, Argenta, as joint legal and beneficial owner with Domantis, hereby assigns to Domantis all its right, title and interest in and to the Joint Patents free from all licences charges or other encumbrances to the intent that the Joint Patents shall be in the name of and shall vest in Domantis to hold unto Domantis absolutely, including

(i) all the rights, powers, liberties and immunities arising or accrued therefrom;

(ii) the right to sue for damages and other remedies in respect of any infringement of such rights or other acts within the scope of the claims of the specifications accompanying the Joint Patents;

(iii) the right to apply for, prosecute and obtain patent, utility model or other similar protection in respect of any invention the subject of the Joint Patents throughout the world; and

(iv) the right to claim priority from any Joint Patent to the intent that the grant of any such patents, utility models or similar protection shall be in the name of and vest in Domantis;

provided that nothing herein shall be construed as the grant of licence, assignment or transfer of the Argenta Technology or any part of it from Argenta to Domantis.

(c) Argenta will give generally to Domantis or any successor in title all such assistance as it may reasonably require in connection with the perfection of Domantis' title to the rights assigned pursuant to Clause 3.1(b) above. Argenta's reasonable costs in providing such assistance will be borne by Domantis.

3.2 Transfer of data. In connection with the assignments set forth above, Argenta agrees to provide to Domantis within ninety (90) days of the Effective Date copies of all Program Results in its possession (e.g. raw data and laboratory notebooks generated by Argenta during the performance of the Research Programs). Argenta shall not be obliged to provide original documents, but to the extent that original documents are not provided, Argenta shall provide copies, certified by a notary public, as true copies of the original. Domantis agrees to reimburse Argenta for all external costs reasonably incurred in complying with this provision.

3.3 License Limitations. No ownership interest or license rights in or to the materials, know-how, technology, patent rights or other intellectual property rights of one Party is transferred to the other Party except as expressly provided in this Agreement. Each Party agrees that it shall not intentionally or knowingly use materials, know-how, technology, patent rights or intellectual property of the other Party licensed hereunder except as expressly permitted under this Agreement or as otherwise allowed in accordance with applicable laws.

3.4 Warranties. Argenta warrants that:

- (a) it is joint legal and beneficial owner of, and owns jointly with Domantis (or such other entity or entities to which Domantis may have transferred the whole or any part of its joint interest) all the rights and interests in, the Joint Property;
- (b) it has not licensed or assigned any of the Joint Property; and
- (c) Argenta's interests in the Joint Property are free from any security interest, option, mortgage, charge or lien.

4. DILIGENCE, COMMERCIALISATION AND REVENUE SHARING

4.1 Overview. Under Clause 6.1 of the JDA, the Parties had previously envisaged that upon one Party terminating its involvement in a Research Program, a licence agreement would be negotiated by the Parties under which exclusive rights would be granted to the continuing Party in consideration for, inter alia, (i) agreed diligence obligations; (ii) a commitment to commercialise by out-licensing to a Third Party before initiation of a Phase III clinical study; and (iii) a pre-agreed sharing of revenues. The Parties have agreed to enter this Agreement in place of that previously envisaged deal structure, and Clause 6 of the JDA shall cease to have any legal effect.

4.2 Revenue Sharing. In consideration for the assignments granted pursuant to Clauses 3.1 and 3.2 above, Domantis shall pay Argenta the sum of One Million Five Hundred Thousand Pounds Sterling (£1,500,000). For the avoidance of doubt, this payment is intended to be a one-off payment in full consideration for the rights in the Joint Property, and Argenta shall have no right to receive any further payments in relation to Joint Property, Collaboration Leads, Products or in any other way arising or relating to the JDA.

4.3 Diligence Obligations. For the avoidance of doubt, Domantis shall not be under any diligence obligations to Argenta and shall have absolute discretion in its further use, development and/or commercialisation (if any) of Joint Property, Collaboration Leads and Products.

4.4 Payments.

(a) All amounts in this contract are stated exclusive of VAT and other indirect taxes. Domantis is responsible for the payment of all such appropriately levied taxes to Argenta.

(b) Domantis shall make all payments under this Agreement within ten (10) days of the date of receipt of a proper invoice. Invoices shall include amounts payable as VAT and all other value added, sales or consumption taxes, which shall be charged in addition according to applicable laws. If Domantis fails to pay any sum due under this Agreement by the due date, Argenta shall be entitled to claim interest on the sum under the Late Payment of Commercial Debts (Interest) Act 1998. Interest shall run from day to day from the due date and shall accrue before and after any judgment and shall be compounded monthly on the amount overdue until payment is made. Argenta's right to claim interest is without prejudice to any other claims under this Agreement.

5. JOINT PATENTS

5.1 Cooperation. Argenta will give generally to Domantis or any successor in title all such assistance as it may reasonably require in connection with the filing, prosecution, maintenance, defence (including any infringement proceedings) and enforcement of Joint Property. Argenta's reasonable costs in providing such assistance will be borne by Domantis.

Nothing in this Agreement shall require Argenta to procure or provide access to any property or information that is no longer within Argenta's control and/or that relates to Argenta Technology.

5.2 Filing, Prosecution and Maintenance of Joint Patents. The Parties agree that from and after the Effective Date, Domantis will have the exclusive right, but not the obligation, at Domantis' cost, to file, prosecute, maintain and defend all Joint Patents in such territories as Domantis determines in its absolute discretion.

5.3 Enforcement of Joint Patents. Domantis shall have the exclusive right, but not the obligation, to bring and control any action or proceeding with respect to infringement of any Joint Patent by counsel of its own choice.

5.4 Joinder, Settlements and Recovery.

(a) For any action by Domantis pursuant to Clause 5.3 above, in the event that Domantis is unable to initiate or prosecute such action solely in its own name, Argenta will join such action voluntarily and will execute and cause its Affiliates to execute all documents necessary for Domantis to initiate, prosecute and maintain such action. Domantis will keep Argenta informed of material developments in any action or proceeding to which Argenta has been joined as a party.

(b) For the avoidance of doubt, Domantis shall have the exclusive right to negotiate a settlement provided that any settlement shall not include any admission of liability on behalf of Argenta, without Argenta's prior written consent.

(c) Domantis shall bear the costs and expenses of any action brought by it as provided above (including, where Domantis has required Argenta to join the action pursuant to Clause 5.4(a) above, the expenses of Argenta's counsel, if any) and shall be entitled to retain any damages or other payments recovered as a result of such action or proceeding.

6. GENERAL PROVISIONS

6.1 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however that Domantis may assign this Agreement and/or any of its rights and obligations hereunder without Argenta's consent to any of its Affiliates, or to a Third Party in connection with the transfer, disposal, licence or sale of Joint Property, whether by merger, sale of stock, sale of assets, licence or otherwise. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be void.

6.2 Confidential Information.

(a) For the purposes of this Agreement, "Confidential Information" shall mean all confidential or proprietary materials or information not generally available to the public that are confidential and proprietary to either Party, including any developed, conceived of, compiled or disclosed during the term of the JDA or this Agreement. Domantis' Confidential Information includes, but is not limited to, all Domantis Technology and, from the Effective Date, all Joint Property. Argenta's Confidential Information includes, but is not limited to, all Argenta Technology. Each Party agrees not to, and agrees to cause its employees, directors, consultants and agents not to, use or disclose the Confidential Information of the other Party for any purposes other than (i) as required in the performance of its duties, or in the exercise of its rights, under this Agreement, or (ii) as expressly permitted in writing by the other Party. These provisions shall not apply to any information disclosed hereunder that: (a)

(with the exception of Joint Property) was known to the receiving Party prior to its date of disclosure by the disclosing Party as evidenced by the receiving Party's written records ; (b) is disclosed lawfully to receiving Party either before or after the date of the disclosure by the disclosing Party, without an obligation of confidentiality by sources (other than the disclosing Party) rightfully in possession of the Confidential Information; (c) is published or generally known to the public, either before or after the date of disclosure through no fault or omission on the part of the receiving Party; (d) (with the exception of Joint Property) is independently developed by the receiving Party without reference to or in reliance upon such Confidential Information; or (e) is required to be disclosed by the receiving Party to comply with applicable laws, to defend or prosecute litigation or to comply with governmental regulations, provided that the receiving Party provides prior written notice of such disclosure to the disclosing Party and takes reasonable and lawful actions to avoid and/or minimize the degree of such disclosure.

(b) The obligations of confidentiality set forth in this Agreement shall survive for a period of five (5) years from the date of this Agreement.

6.3 Governing Law. The validity, construction, performance and all aspects of this Agreement will be governed by English Law. The parties hereby submit to the exclusive jurisdiction of the courts of England.

6.4 Amendments. No amendment, change, modification or alteration of the terms and conditions of this Agreement shall be binding upon either Party unless made in writing and signed by both Parties.

6.5 Non-Waiver. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.

6.6 Entire Agreement. This Agreement constitutes the entire agreement between the Parties relating to the subject matter hereof and supersedes and cancels all previous express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof (including, but not limited to, the JDA). Each of the Parties acknowledges and agrees that in entering into this Agreement, and the documents referred to in it, it does not rely on, and shall have no remedy in respect of, any statement, representation, warranty or understanding (whether negligently or innocently made) of any person (whether party to this Agreement or not) other than as expressly set out in this Agreement. Nothing in this clause shall, however, operate to limit or exclude any liability for fraud.

6.7 Severability. If, for any reason, a court of competent jurisdiction adjudicates any part of this Agreement invalid, unenforceable or illegal, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part.

6.8 Notice. Any notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earlier of: (a) the date of actual receipt; (b) if mailed, five (5) calendar days after the date of postmark; or (c) if delivered by overnight courier, the next business day the overnight courier regularly makes deliveries.

To Argenta:

Pulmagen Therapeutics (Synergy) Limited
Stoke Court
Stoke Pages
Slough, Bucks SL2 4SY
UNITED KINGDOM
Attention: Chief Executive Officer

Fax No. : +44 1279 645646

To Domantis:

Domantis Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UNITED KINGDOM
Attention: VP, Legal Operations,
BioPharm R&D

Fax: +44 20 8047 6897

6.9 Force Majeure. Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party's reasonable control including but not limited to acts of God(s), act(s) of terrorists, fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labour disturbance, or any other event similar to those enumerated above (a "Force Majeure"). Such excuse from liability shall be effective only to the extent and duration of the Force Majeure, provided that the Party has not caused such event(s) to occur. Notice of a Party's failure or delay in performance resulting from the Force Majeure must be given to the other Party within 10 calendar days after its occurrence.

6.10 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and both of which together shall constitute one and the same instrument.

6.11 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instruments, and do such other acts, as may be necessary and appropriate in order to carry out the purposes and intent of this Agreement and to formally register the assignment herein at national and international Patent Offices.

6.12 Costs.


(a) Subject to Clause 6.12(b) below, each Party shall bear its own legal costs and other costs and expenses arising in connection with the drafting, negotiation, execution and registration (if applicable) of this Agreement.


(b) Domantis shall pay Argenta Twenty Thousand Pounds Sterling (£20,000) in support of Argenta's reasonable legal costs incurred in connection with the drafting, negotiation and execution of this Agreement.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized officers as of the date first above written.

DOMANTIS LIMITED

PULMAGEN THERAPEUTICS (SYNERGY) LIMITED
Formerly
ARGENTA DISCOVERY LIMITED

By: 

By: 

Name: Paul Williamson
Authorised Signatory
For and on behalf of Edinburgh Pharmaceutical Industries Limited
Corporate Director

Name: COLIN KNOX

Title: _____

Title: DIRECTOR

Appendix A — Joint Patents

Title: METHODS OF TREATING RESPIRATORY DISEASE USING ANTAGONISTS OF INTERLEUKIN-1 RECEPTOR TYPE 1			
Country	Application Date	Application Number	Publication Number
Australia	01/12/2005	2005311101	AU2005311101
Brazil	01/12/2005	PI0518622-6	BRPI0518622
Canada	01/12/2005	2588892	CA2588892
China P.R.	01/12/2005	200580047653.4	CN101133084
European Patent Convention	01/12/2005	05818379.9	EP1863847
India	29/06/2007	2417/KOLNP/2007	
Japan	01/12/2005	2007543910	JP2008521870
Mexico	01/12/2005	2007006593	MX2007006593
Russian Federation	01/12/2005	2007124730	
Korea South	01/12/2005	20077015202	KR20070086896
United States	29/05/2007	11/791781	US2009191217
Patent Cooperation Treaty	01/12/2005	PCT/GB2005/004601	WO2006059108

Title: TUMOR NECROSIS FACTOR RECEPTOR 1 ANTAGONISTS FOR TREATING RESPIRATORY DISEASES			
Country	Application Date	Application Number	Publication Number
Australia	23/10/2006	2006307733	AU2006307733
Brazil	23/10/2006	PI0617771-9	CA2626939
Canada	23/10/2006	2626939	
China P.R.	23/10/2006	200680048715.8	CN101346397
Eurasian Patent Convention	23/10/2006	200800905	EA200800905
European Patent Convention	23/10/2006	06794871.1	EP1948694
India	23/10/2006	2052/KOLNP/2008	
Israel	23/10/2006	190787	
Japan	23/10/2006	2008-536130	JP2009512672
Korea South	23/10/2006	10-2008-7012242	KR20080066962
Mexico	23/10/2006	MX/a/2008/005129	MX2008005129
New Zealand	23/10/2006	567441	
Norway	23/10/2006	20081836	NO20081836
Patent Cooperation Treaty	23/10/2006	PCT/GB2006/003935	WO2007049017
United States	23/10/2006	12/084084	US20100034831
Great Britain	24/10/2005	GB20050021621	